AN ANALYTICAL STUDY TO COMPARE MATERNAL OUTCOMES WHEN MGSO4 THERAPY AFTER LOADING DOSE IS CONTINUED TO 12 HOURS INSTEAD OF 24 HOURS IN SEVERE PREECLAMPSIA AND ECLAMPSIA

Pregnancy Induced Hypertension (PIH) develops due to pregnancy and regresses after delivery. It is a known cause of premature delivery, intrauterine growth restriction, placental abruption, foetal death and numerous adverse pregnancy outcomes. Maternal complications like oliguria, eclampsia, hemolysis, thrombocytopenia, elevated liver enzymes, pulmonary edema and even death. Previous history of preeclampsia, pre-existing diabetes, obesity, multiple pregnancies has been reported to increase the risk of pregnancy induced hypertension and pre-eclampsia. The aim of the present study was to determine whether decreasing the duration of the MgSO4 regimen to 12 hours instead of 24 hours after the last fit in improving maternal outcome in pre-eclampsia and eclampsia. In the present prospective randomized study, women with severe pre-eclampsia and eclampsia admitted in Department of Obstetrics and Gynecology at IPGME&R, Kolkata, India, was enrolled between April, 2016 to March 2017, selecting the patients on the basis of inclusion and exclusion criteria. Early stoppage of this toxic drug administration which needs constant monitoring in a busy labor room is definitely a major advantage. The shorter postpartum administration of MgSO4 also has the advantages of early ambulation, early removal of urinary catheter and early resumption of nursing of baby and other daily activities with lesser risk of MgSO4 toxicity. The study therefore concludes that the use of short duration postpartum MgSO4 therapy for 12 hours instead of 24 hours with continued hourly maternal monitoring of vital signs.